von Eyben Finn Edler, Virgolini Irene, Baum Richard
Center of Tobacco Control, 5230 Odense, Denmark.
Department of Nuclear Medicine, University Hospital Innsbruck, 6020 Innsbruck, Austria.
Cancers (Basel). 2024 Jul 12;16(14):2520. doi: 10.3390/cancers16142520.
In 2021, two randomized controlled trials (RCTs), TheraP and VISION, demonstrated that Lu-PSMA-617 as monotherapy was more effective for the decline of PSA than the comparator third-line treatments.
Our review summarizes new RCTs that add to the use of radioligand therapy (RLT) for patients with high-risk prostate cancer (PCa).
Four past and present RCTs included 1081 patients. An RCT, ENZA-p, studied first-line treatment of patients with metastatic castration-resistant PCa (mCRPC). A combination of enzalutamide (ENZA) and Lu-PSMA-617 gave longer progression-free survival than ENZA as monotherapy. Other RCTs of patients with mCRPC, including the PSMAfore, and SPLASH trials, showed Lu-PSMA-617 as second-line treatment gave better progression-free survival than androgen receptor pathway inhibitors (combined value < 6.9 × 10).
Patients with PCa gain if they are given PSMA-RLT early in the treatment of PCa and as part of combination therapies.
2021年，两项随机对照试验（RCT），即TheraP和VISION试验，表明镥-PSMA-617作为单一疗法在降低前列腺特异性抗原（PSA）方面比对照三线治疗更有效。
我们的综述总结了新的随机对照试验，这些试验增加了放射性配体疗法（RLT）在高危前列腺癌（PCa）患者中的应用。
四项过去和现在的随机对照试验纳入了1081名患者。一项随机对照试验ENZA-p研究了转移性去势抵抗性前列腺癌（mCRPC）患者的一线治疗。恩杂鲁胺（ENZA）和镥-PSMA-617联合使用比单独使用ENZA的无进展生存期更长。其他mCRPC患者的随机对照试验，包括PSMAfore和SPLASH试验，表明镥-PSMA-617作为二线治疗比雄激素受体通路抑制剂的无进展生存期更好（合并值<6.9×10）。
前列腺癌患者如果在前列腺癌治疗早期接受PSMA-RLT并作为联合治疗的一部分，将会获益。
